New report recognizes best hospitals in Houston

better than all the rest

Houston Methodist stood out yet again on an annual best hospitals report, but several other Houston institutions were recognized as well. Courtesy of Methodist Hospital/Facebook

Hospitals across Houston were ranked by their patient care, patient safety, outcomes, nursing, advanced technology and reputation in an annual report that identifies the top medical facilities in the country.

U.S. News & World Report released its 31st annual best hospital rankings this week, which included both adult and children's hospital tracks across several categories. The report released both overall and local rankings after evaluating over 4,500 medical centers nationwide in 16 specialties, and 134 hospitals were ranked in at least one specialty.

For the ninth year in a row, the top hospital in Houston and Texas, according to the report, is Houston Methodist, which ranked at No. 20 nationally and made the report's Honor Roll.

"Our U.S. News rankings are especially meaningful right now as this has been an exceptionally difficult time for our health care workers," says Marc Boom, M.D., president and CEO of Houston Methodist, in a news release. "We have always served our community by providing exceptional care — during the COVID-19 pandemic and before. It's a true testament to our commitment to being unparalleled."

Houston Methodist Sugar Land Hospital tied for No. 4 in Houston and No. 6 (three-way tie) in Texas. Additionally, the hospital was recognized on the top lists for 11 specialties:

  • No. 12 for cardiology/heart surgery
  • No. 13 for orthopedics
  • No. 14 for gastroenterology/GI surgery
  • No. 17 for cancer
  • No. 19 (tie) for nephrology
  • No. 20 for pulmonology and lung surgery
  • No. 23 for neurology/neurosurgery
  • No. 26 for geriatrics
  • No. 26 (tie) for gynecology
  • No. 28 for diabetes and endocrinology
  • No. 49 for ear, nose and throat

The second-best hospital in Houston on this year's ranking was Baylor St. Luke's Medical Center, which was also named the No. 3 hospital in the state.

"At Baylor St. Luke's, we are transforming the way we deliver care for our patients through groundbreaking technologies and a multidisciplinary approach that allows us to give the best possible care to patients and their families," says Doug Lawson, CEO of St. Luke's Health, in a news release. "I praise our dedicated staff and physicians for helping us achieve this recognition."

Baylor St. Luke's also made an appearance across five specialties:

  • No. 17 for cardiology/heart surgery
  • No. 21 for gastroenterology/GI surgery
  • No. 21 for neurology/neurosurgery
  • No. 27 for cancer
  • No. 47 for geriatrics

"This is a great report that confirms the efforts of our partnership at Baylor St. Luke's and our affiliated hospitals to provide unsurpassed care to patients, conduct research that will change lives and train the next generation of physicians", says Dr. Paul Klotman, president, CEO, and executive dean at Baylor College of Medicine. "Baylor St. Luke's high ranking in Texas is in parallel with Baylor College of Medicine being the highest ranked medical school in Texas. Together, we are an outstanding academic medical center and learning health system."

Memorial Hermann - Texas Medical Center came in No. 3 in Houston and No. 5 in Texas. The hospital ranked in one adult specialty and two children's specialties.

  • No. 43 for ear, nose and throat (adult)
  • No. 22 for cardiology/heart surgery (pediatric)
  • No. 31 for neurology/neurosurgery (pediatric)

On the children's hospital track, Houston's Texas Children's Hospital ranked as No. 4 nationally and was recognized in all 10 pediatric specialties, which included:

  • No. 1 for pediatric cardiology/heart surgery
  • No. 2 for pediatric nephrology
  • No. 2 for pediatric neurology/neurosurgery
  • No. 3 for pediatric pulmonology and lung surgery
  • No. 4 for pediatric cancer
  • No. 5 for pediatric diabetes and endocrinology
  • No. 5 for pediatric gastroenterology/GI surgery
  • No. 6 for pediatric urology
  • No. 10 for neonatology
  • No. 15 for pediatric orthopedics

Zooming in on the specific specialties, several other Houston hospitals in addition to these top tier hospitals, secured spots in the top 10 rankings.

University of Texas MD Anderson Cancer Center was ranked No. 1 nationally for adult cancer treatment. Additionally, the hospital made an appearance in six other adult specialties and one pediatric specialty.

  • No. 4 for ear, nose and throat
  • No. 6 for urology
  • No. 14 for gynecology
  • No. 27 for diabetes and endocrinology
  • No. 41 for geriatrics
  • No. 46 for gastroenterology/GI surgery
  • No. 38 for cancer (pediatric)
TIRR Memorial Hermann in Houston ranked No. 3 nationally for rehabilitation.
For all 31 years, The Menninger Clinic has been recognized as a top hospital in the psychiatric speciality. This year, the clinic ranked at No. 9 nationally.

"Our clinical teams provide personalized care with the right blend of art and science. We have pioneered measuring the effectiveness of this treatment, and the results consistently demonstrate that patients sustain their well-being for at least a year after they leave Menninger," says Armando Colombo, president and CEO, in a news release. "Going forward, we will improve access to make it easier for more Texans to access these life-changing results."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.